Reply:

References

1. 1.↵
   1. Alves C,
   2. Zandifar A,
   3. Peterson JT, et al

   . MELAS: phenotype classification into classic-versus-atypical presentations. AJNR Am J Neuroradiol 2023;44:602–10 doi:10.3174/ajnr.A7837 pmid:37024306

   Abstract/FREE Full Text
2. 2.↵
   1. Mavraki E,
   2. Labrum R,
   3. Sergeant K, et al

   . Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. Eur J Hum Genet 2023;31:148–63 doi:10.1038/s41431-022-01249-w pmid:36513735

   CrossRefPubMed
3. 3.↵
   1. Hirano M,
   2. Ricci E,
   3. Koenigsberger MR, et al

   . Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992;2:125–35 doi:10.1016/0960-8966(92)90045-8

   CrossRefPubMed
4. 4.↵
   1. Yatsuga S,
   2. Povalko N,
   3. Nishioka J, et al

   ; Taro Matsuoka for MELAS Study Group in Japan. MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 2012;1820:619–24 doi:10.1016/j.bbagen.2011.03.015 pmid:21443929

   CrossRefPubMed
5. 5.↵
   1. De Vries MC,
   2. Brown DA,
   3. Allen ME, et al

   . Safety of drug use in patients with a primary mitochondrial disease: an international Delphi-based consensus. J Inherit Metab Dis 2020;43:800–18 doi:10.1002/jimd.12196 pmid:32030781

   CrossRefPubMed